

Filed on behalf of: Corcept Therapeutics, Inc.

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TEVA PHARMACEUTICALS USA, INC.,
Petitioner

v.

CORCEPT THERAPEUTICS, INC.,
Patent Owner

Case PGR2019-00048
U.S. Patent No. 10,195,214

PATENT OWNER'S EXHIBIT LIST

EX	Description
2001	August 2018 Update to the Office Patent Trial Practice Guide, 83 Fed. Reg. 39,989 (Aug. 13, 2018)
2002	Chart Comparing Arguments Made By Petitioner in PGR2019-00048 and in the District Court Litigation
2003	January 16, 2019 Email from U. Everett to Counsel
2004	<i>Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc.</i> , No. 18-cv-3632, D.I. 31 (D.N.J. Oct. 23, 2018)
2005	<i>Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc.</i> , No. 18-cv-3632, D.I. 73 (D.N.J. June 4, 2019)
2006	R. Pivonello et al., “The Treatment of Cushing’s Disease,” <i>Endocrine Rev.</i> , 36(4):385-486 (2015)
2007	D. Guelho & A. Grossman, “Emerging Drugs for Cushing’s disease,” <i>Exp. Op. on Emerging Drugs</i> , 20(3):463-78 (2015)
2008	M. Fleseriu & S. Petersenn, “New Avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy,” <i>J. Neurooncol.</i> , 114:1-11 (2013)
2009	R.A. Felders et al., “The burden of Cushing’s disease: clinical and health-related quality of life aspects,” <i>Eur. J. Endocrinol.</i> , 167:311-26 (2012)
2010	“Hyperglycemia in Diabetes,” The Mayo Clinic (Nov. 3, 2018), https://www.mayoclinic.org/diseases-conditions/hyperglycemia/symptoms-causes/syc-20373631
2011	D. Cuevas-Ramos et al., “Update on medical treatment for Cushing’s disease,” <i>Clin. Diabetes & Endocrinol.</i> , 2:16 (2016)
2012	M. Fleseriu et al., “A New Therapeutic Approach in the Medical Treatment of Cushing’s Syndrome: Glucocorticoid Receptor Blockade with Mifepristone,” <i>Endocrine Practice</i> , 19(2):313-26 (2013)
2013	O. Heikinheimo et al., “The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogesterin action,” <i>Contraception</i> , 68:421-26 (2003)
2014	U.S. Patent No. 8,921,348 (“Optimizing Mifepristone Levels in Plasma Serum of Patients Suffering from Mental Disorders Treatable with Glucocorticoid Receptor Antagonists”)

2015	X. Bertagna et al., "Chapter 16: Cushing's Disease," in THE PITUITARY (Shlomo Melmed ed., 3rd ed. 2011)
2016	J.K. Oosterhuis et al., "Life-threatening <i>Pneumocystis jiroveci</i> pneumonia following treatment of severe Cushing's syndrome," <i>Netherlands J. Med.</i> , 65(6):215-17 (2007)
2017	Biaxin (clarithromycin) Full Prescribing Information (May 2016)
2018	Sporanox (itraconazole) Full Prescribing Information (April 2015)
2019	Nizoral (ketoconazole) Full Prescribing Information (2013)
2020	E. Charmandari et al., "Adrenal Insufficiency," <i>Lancet</i> , 383(9935):2152-67 (2014)
2021	A. Viera et al., "Potassium Disorders: Hypokalemia and Hyperkalemia," <i>American Family Physician</i> , 92(6):487-95 (2015)
2022	M. Basina et al., "Successful Long-Term Treatment of Cushing Disease with Mifepristone (RU486)," <i>Endocrine Practice</i> , 18(5):114-20 (2012)
2023	D. Greenblatt & J. Harmatz, "Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies," <i>Brit. J. Clin. Pharmacol.</i> , 80(3):342-50 (2015)
2024	Incivek (telaprevir) Full Prescribing Information (October 2013)
2025	VFEND (voriconazole) Full Prescribing Information (February 2015)
2026	Victrelis (boceprevir) Full Prescribing Information (January 2017)
2027	Tybost (cobicistat) Full Prescribing Information (June 2016)
2028	Vaprisol (conivaptan hydrochloride) Full Prescribing Information (October 2016)
2029	Crixivan (indinavir sulfate) Full Prescribing Information (September 2016)
2030	Kaletra (lopinavir and ritonavir) Full Prescribing Information (November 2016)
2031	Viracept (nelfinavir mesylate) Full Prescribing Information (September 2016)
2032	Technivie (ombitasvir, paritaprevir and ritonavir) Full Prescribing Information (February 2017)

2033	Invirase (saquinavir mesylate) Full Prescribing Information (September 2016)
2034	D. Cuevas-Ramos & M. Fleseriu, "Treatment of Cushing's disease: a mechanistic update," <i>J. Endocrinol.</i> , 223(2):R19-39 (2014)
2035	T. Carroll & J.W. Findling, "The Use of Mifepristone in the Treatment of Cushing's Syndrome," <i>Drugs of Today</i> , 48(8):509-18 (2012)
2036	E. Dunnigan et al., "Mifepristone (RU-486) in the treatment of Refractory Cushing's Disease," <i>Endocrine Rev., Suppl. 1</i> , 31(3):S1201 (2010)
2037	Nefazodone Hydrochloride Tablets Full Prescribing Information (May 2014)
2038	Noxafil (posaconazole) Full Prescribing Information (September 2016)
2039	Norvir (ritonavir) Full Prescribing Information (December 2016)
2040	Excerpts of Physician's Desk Reference (58th ed. 2004)
2041	"The Hazards of Seldane," N.Y. TIMES (January 17, 1997)
2042	European Medicines Agency, "European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole," July 26, 2013
2043	M. Tran & J. Grillo, "Translation of Drug Interaction Knowledge to Actionable Labeling," <i>Clin. Pharmacol. & Therapeutics</i> , 105(6):1292-95 (2019)
2044	M. Fleseriu et al., "Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mifepristone," <i>J. Clin. Endocrinol. Metab.</i> , 99(10):3718-27 (2014)
2045	"Treatment for Aspergillosis," Centers for Disease Control and Prevention (Jan. 2, 2019), https://www.cdc.gov/fungal/diseases/aspergillosis/treatment.html
2046	"Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers," U.S. Food and Drug Administration (Nov. 14, 2017), https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers
2047	September 6, 2019 Email from D. Sterling to Counsel

Date: October 3, 2019

Respectfully Submitted,



F. Dominic Cerrito (Reg. No. 38,100)
Eric C. Stops (Reg. No. 51,163)
Daniel C. Wiesner (pro hac vice)
Frank C. Calvosa (Reg. No. 69,064)
John Galanek (Reg. No. 74,512)
QUINN EMANUEL URQUHART &
SULLIVAN, LLP
51 Madison Avenue, 22nd Floor
New York, NY 10010
Tel: (212) 849-7000
Fax: (212) 849-7100
nickcerrito@quinnemanuel.com
ericstops@quinnemanuel.com
danielwiesner@quinnemanuel.com
frankcalvosa@quinnemanuel.com
johngalanek@quinnemanuel.com

Counsel for Patent Owner

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.